RESUMO
In the first wave of COVID-19, up to 20% of patients had skin lesions with variable characteristics. There is no clear evidence of the involvement of the SARS-CoV-2 virus in all cases; some of these lesions may be secondary to drug hypersensitivity. To analyze the possible cause of the skin lesions, we performed a complete allergology study on 11 patients. One year after recovery from COVID-19, we performed a lymphocyte transformation test (LTT) and Th1/Th2 cytokine secretion assays for PBMCs. We included five nonallergic patients treated with the same drugs without lesions. Except for one patient who had an immediate reaction to azithromycin, all patients had a positive LTT result for at least one of the drugs tested (azithromycin, clavulanic acid, hydroxychloroquine, lopinavir, and ritonavir). None of the nonallergic patients had a positive LTT result. We found mixed Th1/Th2 cytokine secretion (IL-4, IL-5, IL-13, and IFN-γ) in patients with skin lesions corresponding to mixed drug hypersensitivity type IVa and IVb. In all cases, we identified a candidate drug as the culprit for skin lesions during SARS-CoV-2 infection, although only three patients had a positive drug challenge. Therefore, it would be reasonable to recommend avoiding the drug in question in all cases.
Assuntos
COVID-19 , Hipersensibilidade a Drogas , Humanos , Azitromicina/efeitos adversos , Ativação Linfocitária , SARS-CoV-2 , Hipersensibilidade a Drogas/diagnóstico , Hipersensibilidade a Drogas/etiologia , Citocinas , Teste para COVID-19Assuntos
Alérgenos , Hipersensibilidade , Animais , Humanos , Carboxipeptidase B , Ouriços , Vesículas Secretórias , LectinasAssuntos
Infecções por Coronavirus/tratamento farmacológico , Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico , Pneumonia Viral/tratamento farmacológico , Betacoronavirus , COVID-19 , Humanos , Injeções Subcutâneas , Proteína Antagonista do Receptor de Interleucina 1/administração & dosagem , Masculino , Pessoa de Meia-Idade , Pandemias , SARS-CoV-2 , Resultado do TratamentoRESUMO
INTRODUCTION AND OBJECTIVES: Some anthropometric measurements show a greater capacity than others to identify the presence of cardiovascular risk factors. This study estimated the magnitude of the association of different anthropometric indicators of obesity with hypertension, dyslipidemia, and prediabetes (altered fasting plasma glucose and/or glycosylated hemoglobin). METHODS: Cross-sectional analysis of information collected from 2022 participants in the PREDAPS study (baseline phase). General obesity was defined as body mass index ≥ 30kg/m2 and abdominal obesity was defined with 2 criteria: a) waist circumference (WC) ≥ 102cm in men/WC ≥ 88cm in women, and b) waist-height ratio (WHtR) ≥ 0.55. The magnitude of the association was estimated by logistic regression. RESULTS: Hypertension showed the strongest association with general obesity in women (OR, 3.01; 95%CI, 2.24-4.04) and with abdominal obesity based on the WHtR criterion in men (OR, 3.65; 95%CI, 2.66-5.01). Hypertriglyceridemia and low levels of high-density lipoprotein cholesterol showed the strongest association with abdominal obesity based on the WHtR criterion in women (OR, 2.49; 95%CI, 1.68-3.67 and OR, 2.70; 95%CI, 1.89-3.86) and with general obesity in men (OR, 2.06; 95%CI, 1.56-2.73 and OR, 1.68; 95%CI, 1.21-2.33). Prediabetes showed the strongest association with abdominal obesity based on the WHtR criterion in women (OR, 2.48; 95%CI, 1.85-3.33) and with abdominal obesity based on the WC criterion in men (OR, 2.33; 95%CI, 1.75-3.08). CONCLUSIONS: Abdominal obesity indicators showed the strongest association with the presence of prediabetes. The association of anthropometric indicators with hypertension and dyslipidemia showed heterogeneous results.
Assuntos
Dislipidemias/etiologia , Hipertensão/etiologia , Obesidade Abdominal/complicações , Estado Pré-Diabético/etiologia , Medição de Risco , Adulto , Idoso , Antropometria , Estudos Transversais , Dislipidemias/epidemiologia , Feminino , Humanos , Hipertensão/epidemiologia , Incidência , Masculino , Pessoa de Meia-Idade , Obesidade Abdominal/epidemiologia , Estado Pré-Diabético/epidemiologia , Prognóstico , Fatores de Risco , Espanha/epidemiologiaRESUMO
BACKGROUND: Left ventricular hypertrophy (LVH) is an important predictor of cardiovascular risk, and its detection contributes to risk stratification. The aims of the present study were to estimate the prevalence of echocardiographic LVH and to evaluate the influence of echocardiography (ECHO) on cardiovascular risk stratification in hypertensive patients presenting in primary care. METHODS: In this cross-sectional study, 250 patients recently diagnosed with mild hypertension underwent clinical evaluation including electrocardiography (ECG), microalbuminuria measurement, 24-h blood pressure monitoring and ECHO. Level of cardiovascular risk was stratified, initially using routine procedures including ECG to assess target organ damage and then again after detection of LVH by ECHO. RESULTS: The frequency of echocardiographic LVH was 32%, substantially higher than that detected by ECG (9%). Initial cardiovascular risk stratification yielded the following results: 30% low risk, 49% medium risk, 16% high risk, and 5% very high risk subjects. The detection of LVH by ECHO provoked a significant change in the risk strata distribution, particularly in those patients initially classified as being at medium risk. In this group, 40% of subjects were reclassified as high risk subjects according to ECHO information. The new classification was as follows: 23% low risk, 30% medium risk, 42% high risk, and 5% very high risk subjects. CONCLUSIONS: A substantial proportion of mildly hypertensive patients presenting in primary care have LVH determined by ECHO. Our results suggest that this procedure could significantly improve cardiovascular risk stratification in those patients with multiple risk factors, but no evidence of target organ damage by routine investigations.
Assuntos
Hipertensão/complicações , Hipertrofia Ventricular Esquerda/epidemiologia , Albuminúria , Monitorização Ambulatorial da Pressão Arterial , Estudos Transversais , Ecocardiografia , Feminino , Humanos , Hipertrofia Ventricular Esquerda/diagnóstico , Hipertrofia Ventricular Esquerda/diagnóstico por imagem , Hipertrofia Ventricular Esquerda/etiologia , Masculino , Pessoa de Meia-Idade , Exame Físico , Prevalência , Atenção Primária à Saúde , Medição de RiscoRESUMO
Introducción y objetivos: Algunas medidas antropométricas muestran mayor capacidad que otras para discriminar la presencia de factores de riesgo cardiovascular. Este trabajo estima la magnitud de la asociación de diversos indicadores antropométricos de obesidad con hipertensión, dislipemia y prediabetes (glucemia basal o glucohemoglobina alteradas). Métodos: Análisis transversal de la información recogida en 2.022 sujetos del estudio PREDAPS (etapa basal). Se definió obesidad general como índice de masa corporal ≥ 30 kg/m2 y obesidad abdominal con 2 criterios: a) perímetro de cintura (PC) ≥ 102 cm en varones/PC ≥ 88 cm en mujeres, y b) índice cintura/estatura (ICE) ≥ 0,55. La magnitud de la asociación se estimó mediante regresión logística. Resultados: La hipertensión arterial mostró la asociación más alta con la obesidad general en mujeres (OR = 3,01; IC95%, 2,24-4,04) y con la obesidad abdominal según el criterio del ICE en varones (OR = 3,65; IC95%, 2,66-5,01). La hipertrigliceridemia y los valores bajos de colesterol unido a lipoproteínas de alta densidad mostraron la asociación más alta con obesidad abdominal según el criterio del ICE en mujeres (OR = 2,49; IC95%, 1,68-3,67 y OR = 2,70; IC95%, 1,89-3,86) y la obesidad general en varones (OR = 2,06; IC95%, 1,56-2,73 y OR = 1,68; IC95%, 1,21-2,33). La prediabetes mostró la asociación más alta con obesidad abdominal según el criterio del ICE en mujeres (OR = 2,48; IC95%, 1,85-3,33) y con obesidad abdominal según el criterio del PC en varones (OR = 2,33; IC95%, 1,75-3,08). Conclusiones: Los indicadores de obesidad abdominal mostraron la mayor asociación con la presencia de prediabetes. La relación de los indicadores antropométricos con hipertensión y con dislipemia mostró resultados heterogéneos (AU)
Introduction and objectives: Some anthropometric measurements show a greater capacity than others to identify the presence of cardiovascular risk factors. This study estimated the magnitude of the association of different anthropometric indicators of obesity with hypertension, dyslipidemia, and prediabetes (altered fasting plasma glucose and/or glycosylated hemoglobin). Methods: Cross-sectional analysis of information collected from 2022 participants in the PREDAPS study (baseline phase). General obesity was defined as body mass index ≥ 30 kg/m2 and abdominal obesity was defined with 2 criteria: a) waist circumference (WC) ≥ 102 cm in men/WC ≥ 88 cm in women, and b) waist-height ratio (WHtR) ≥ 0.55. The magnitude of the association was estimated by logistic regression. Results: Hypertension showed the strongest association with general obesity in women (OR, 3.01; 95%CI, 2.24-4.04) and with abdominal obesity based on the WHtR criterion in men (OR, 3.65; 95%CI, 2.66-5.01). Hypertriglyceridemia and low levels of high-density lipoprotein cholesterol showed the strongest association with abdominal obesity based on the WHtR criterion in women (OR, 2.49; 95%CI, 1.68-3.67 and OR, 2.70; 95%CI, 1.89-3.86) and with general obesity in men (OR, 2.06; 95%CI, 1.56-2.73 and OR, 1.68; 95%CI, 1.21-2.33). Prediabetes showed the strongest association with abdominal obesity based on the WHtR criterion in women (OR, 2.48; 95%CI, 1.85-3.33) and with abdominal obesity based on the WC criterion in men (OR, 2.33; 95%CI, 1.75-3.08). Conclusions: Abdominal obesity indicators showed the strongest association with the presence of prediabetes. The association of anthropometric indicators with hypertension and dyslipidemia showed heterogeneous results (AU)
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Hipertensão/epidemiologia , Hipertensão/prevenção & controle , Obesidade/complicações , Hiperlipidemias/complicações , Estado Pré-Diabético/diagnóstico , Obesidade Abdominal/complicações , Hiperlipidemias/prevenção & controle , Estado Pré-Diabético/prevenção & controle , Antropometria/métodos , Razão Cintura-Estatura , Modelos Logísticos , Glicemia/metabolismoRESUMO
Las hemoglobinopatías son alteraciones cualitativas o cuantitativas de las cadenas de hemoglobina, estimándose que anualmente nacen en todo el mundo 200 millones de personas portadoras de esta alteración (heterocigotos) y 200 a 300 mil personas que padecen la enfermedad (homocigotos) Clínicamente las más importantes de todas las hemoglobinopatías son: la anemia de células falciformes (ACF) y las alfa y beta talasemias; siendo de mayor incidencia que otras enfermedades congénitas frecuentes y graves como el hipotiroidismo congénito y la fenilcetonuria. La ACF es un defecto heredado en forma recesiva, que afecta a uno de cada 400.900 recién nacidos en poblaciones de riesgo que son: las de raza negra (africanos, quienes pueden alcanzar una prevalencia del 40 por ciento o negros inmigrantes en América con una prevalencia del 8 por ciento); o aquéllas con una alta frecuencia de mezclas raciales, como son la de América Central y del Sur, donde pueden tener una prevalencia del 6 por ciento. En Colombia se han realizado algunos estudios aislados, especialmente en la región de la Costa Pacífica, encontrando una prevalencia aproximada del 10 por ciento al 18 por ciento. Esta patología presenta una alta tasa de morbimortalidad, especialmente en los tres primeros años de vida, cuando no se realiza un diagnóstico y tratamiento rápido y adecuado de las principales complicaciones (infecciones por gérmenes encapsulados; crisis vaso-oclusivas con lesión orgánica a largo plazo; crisis de secuestro esplénico o hemolíticas y crisis aplásticas); o una adecuada profilaxis de estas mismas especialmente la educación sobre los signos y síntomas de alerta que ameritan consulta inmediata y un seguimiento clínico multidisciplinario. Esta alta morbimortalidad puede reducirse sustancialmente al realizarse un diagnóstico temprano. El diagnóstico precoz puede hacerse en forma prenatal, implicando procedimientos que no están exentos de riesgo para la madre y el feto, que requieren instituciones de tercer nivel y mayores costos (amniocentesis, biopsia de vellosidades coriónicas); o postnatal, utilizando muestras de sangre de cordón o capilares de fácil recolección y sin complicaciones. El análisis de laboratorio puede realizarse por diversos métodos, de los cuales la prueba de elección sigue siendo la electroforesis en acetato de celulosa. El diagnóstico temprano permite además el estudio de la familia (para identificación de portadores), consejería genética y educación.